Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIN-1 is a human norovirus challenge pool derived from the GII.4 genotype, specifically developed by the Cincinnati Children's Hospital Medical Center. It is utilized in controlled human infection models (CHIM) to evaluate the efficacy of norovirus vaccines and antiviral candidates. The pool was prepared from a stool sample of an infected individual (isolate 031693) and is administered orally to healthy, susceptible volunteers to determine the infectious dose and characterize the clinical course of norovirus-induced gastroenteritis. As a challenge agent, it serves as a standardized tool for clinical research rather than a therapeutic intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Norovirus challenge pool (GII.4, CIN-1).